Coelho Rogerio Vivaldi - 12 Mar 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
12 Mar 2026
Net transactions value
-$180,761
Form type
4
Filing time
13 Mar 2026, 17:46:09 UTC
Previous filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vivaldi Coelho Rogerio Director C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 13 Mar 2026 0001610381

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale $161,530 -4,477 -21% $36.08 16,823 12 Mar 2026 Direct F1, F2
transaction CRNX Common Stock Sale $19,231 -523 -3.1% $36.77 16,300 12 Mar 2026 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
F2 The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on the transaction date was $35.65 to $36.53 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F3 The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on the transaction date was $36.69 to $36.89 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.